Medicus Pharma has submitted a key regulatory package in Europe to start a Phase 2b clinical trial of Teverelix for advanced prostate cancer patients with elevated cardiovascular risk. This study aims to optimize dosing and gather data to support future drug registration, addressing a significant unmet need as cardiovascular disease is a leading cause of death in this patient group. The trial, planned mainly in Europe, will assess testosterone and follicle-stimulating hormone suppression, focusing on safety and efficacy. Successful trial progress could advance Medicus Pharma's strategy to differentiate Teverelix in a market lacking therapies specifically labeled for patients with cardiovascular risk.
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
